Physician profile
Scott Huffer
NPI 1962611483
$3,303.23
in general payments reported to CMS, 2019-2025
22 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $347 · 2021: $318 · 2022: $501 · 2023: $264 · 2024: $881 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $476.51 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $326.35 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $312.43 | 2022-2025 | Infuse, Miebo, Xiidra |
| Alcon Vision LLC | $284.09 | 2019-2025 | Dailies Total1, Precision 1, Rocklatan |
| Oyster Point Pharma, INC. | $262.19 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $228.23 | 2019-2025 | Cequa |
| Biotissue Holdings INC. | $222.79 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $213.05 | 2019-2023 | |
| Dompe US, INC. | $191.59 | 2021-2025 | Oxervate |
| Allergan, INC. | $186.53 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $93.24 | 2024-2025 | Xdemvy |
| Samsara Vision | $81.62 | 2024 | |
| Glaukos Corporation | $74.13 | 2024 | Radius |
| Kala Pharmaceuticals, INC. | $65.86 | 2021 | |
| Thea Pharma INC. | $61.24 | 2024-2025 | Iyuzeh |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Maculogix, INC. | $61.08 | 2019 | |
| Aerie Pharmaceuticals, INC. | $54.32 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $40.53 | 2019-2022 | |
| Abbvie INC. | $22.11 | 2022 | |
| Visioneering Technologies, INC. | $18.72 | 2019 | |
| Quidel Corporation | $13.90 | 2021 | |
| Shire North American Group INC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Huffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.